Biopharmaceutical company Coherus BioSciences has agreed to divest its ophthalmology franchise, Cimerli, to pharmaceutical company Sandoz for $170 million.
Coherus to divest ophthalmology business for $170M
Biopharmaceutical company Coherus BioSciences has agreed to divest its ophthalmology franchise, Cimerli, to pharmaceutical company Sandoz for $170 million.